- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02208427
Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan
Background:
Tuberculosis (TB) remains the most important infectious disease in the world. Keys to successful control of TB is rapid diagnosis, prompt treatment, as well as effective preventive therapy for contacts with latent TB infection (LTBI). Current methods for the diagnosis of LTBI are tuberculin skin test (TST) and interferon-gamma release assay (IGRA). For preventive therapy, the recommended regimens include daily isoniazid for 9 months and daily rifampicin for 4 months. By incorporating long-acting rifapentine, a new regimen combining weekly rifapentine and high-dose isoniazid for a total of 12 doses has been proven of equal potency and toxicity. However, the treatment completion rate is much higher in weekly treatment for 3 months than daily treatment for 9 months. It is reasonable that using rifapentine-based preventive therapy can markedly increase the completion rate. However, study is lacking, especially in Asia, the high endemic area of TB.
With the effort of all health care workers and public health personnel, the incidence of TB in Taiwan has gradually declined in recent 10 years. In order to maintain the trend of decreasing in incidence, preventive therapy for LTBI become more and more important. However, which is the best preventive regimen for LTBI is still unknown. Therefore, we conduct the prospective randomized multicenter studies to compare the treatment completion rate of two regimens in Taiwan. The first regimen is daily isoniazid for 9 months. The second is weekly rifapentine plus high-dose isoniazid for 3 months.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
Tuberculosis (TB) remains the most important infectious disease in the world. Keys to successful control of TB is rapid diagnosis, prompt treatment, as well as effective preventive therapy for contacts with latent TB infection (LTBI). Current methods for the diagnosis of LTBI are tuberculin skin test (TST) and interferon-gamma release assay (IGRA). For preventive therapy, the recommended regimens include daily isoniazid for 9 months and daily rifampicin for 4 months. By incorporating long-acting rifapentine, a new regimen combining weekly rifapentine and high-dose isoniazid for a total of 12 doses has been proven of equal potency and toxicity. However, the treatment completion rate is much higher in weekly treatment for 3 months than daily treatment for 9 months. It is reasonable that using rifapentine-based preventive therapy can markedly increase the completion rate. However, study is lacking, especially in Asia, the high endemic area of TB.
With the effort of all health care workers and public health personnel, the incidence of TB in Taiwan has gradually declined in recent 10 years. In order to maintain the trend of decreasing in incidence, preventive therapy for LTBI become more and more important. However, which is the best preventive regimen for LTBI is still unknown. Therefore, we conduct the prospective randomized multicenter studies to compare the treatment completion rate of two regimens in Taiwan. The first regimen is daily isoniazid for 9 months. The second is weekly rifapentine plus high-dose isoniazid for 3 months.
Specific Aims:
- Understanding which of the two preventive regimens has the highest completion rate under supervision.
- Understanding the reasons of interruption in preventive therapy.
- Comparing the side effect profile of the two preventive regimens in Taiwan.
Methods:
In this prospective multicenter study, we will enroll close contacts aged >=12 with positive TST. Chest radiography and sputum studies, if necessary, will be performed to exclude active pulmonary TB. After performing baseline IGRA, participants will be randomized into 2 groups with different preventive regimens. The first regimen is daily isoniazid for 9 months. The second is weekly rifapentine plus high-dose isoniazid for 3 months. The primary outcome is treatment completion rate of the two preventive regimens. The secondary outcome is toxicity. All participant will be followed for 2 years and screen for the development of active pulmonary TB by chest radiography and sputum studies if necessary. The reasons for treatment incompletion will be recorded.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 100
- National Taiwan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Household contacts of TB or TB contacts in schools or densely-populated institutes
- Age ≥12 year-old
- Index case having smear-positive pulmonary TB
- Contact with index case for >8 hours within single day or >40 hours within total transmissible period
- TST ≥10 mm within one month
- Born in 1986 or after (not applicable in the National Taiwan University Hospital Hsin-Chu branch and Chang-Hua Hospital)
Exclusion Criteria:
- Clinical or radiographic evidence of active TB
- Index case having culture-negative pulmonary TB
- Index case having Isoniazid or Rifampin-resistant TB
- Receiving medications with significant interactions with Isoniazid, Rifampin, or Rifapentine
- Allergy to Isoniazid, Rifampin, or Rifapentine
- Sero-positive for hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Documented liver cirrhosis
- Human immunodeficiency virus (HIV) infection
- Receiving immunosuppressants
- Receiving biological agents
- Hemoglobin <8 g/dL
- Neutrophil <750000 /mL
- Total bilirubin >2.5 mg/dL
- Aspartic transaminase (AST) or alanine transaminase (ALT) >2 folds of upper limit of normal (ULN)
- Pregnant or breast-feeding
- Life expectancy <3 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 3M_RH
Rifapentine and Isoniazid for 3 months: weekly oral rifapentine 15 mg/kg plus isoniazid 15 mg/kg for 12 doses
|
weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
Other Names:
|
Active Comparator: 9M_INH
Isoniazid for 9 months: daily oral isoniazid 5 mg/kg for 9 months
|
daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
completion rate
Time Frame: 2 years
|
This prospective randomized interventional study is aimed to assess the completion rate of two different preventive regimens for LTBI by intent-to-treat analysis.
Interruption of preventive therapy due to any reasons will be considered as incompletion.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
side effect
Time Frame: 3 months in the 3M_RH group and 9 months in the 9M_INH group
|
To evaluate the side effect profile (especially hepatotoxicity, defined as AST and/or ALT ≥2 ULN) of the two preventive regimens
|
3 months in the 3M_RH group and 9 months in the 9M_INH group
|
interruption
Time Frame: 3 months in the 3M_RH group and 9 months in the 9M_INH group
|
To calculate the number of participants with interruption in preventive therapy and to know the reasons of interruption by questionnaire
|
3 months in the 3M_RH group and 9 months in the 9M_INH group
|
active TB
Time Frame: 2 years after enrollment
|
To know the rate of active TB within subsequent 2 years
|
2 years after enrollment
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jann-Yuan Wang, MD. PhD., National Taiwan University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Latent Infection
- Tuberculosis
- Latent Tuberculosis
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- Leprostatic Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Fatty Acid Synthesis Inhibitors
- Rifapentine
- Isoniazid
Other Study ID Numbers
- 201309055MINC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Latent Tuberculosis Infection
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Recruiting
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Shenzhen Third People's Hospital; Wuhan Institute for Tuberculosis ControlRecruitingLatent Tuberculosis InfectionChina
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingHealthy | Latent Tuberculosis Infection (LTBI)United States
-
McGill UniversityCanadian Institutes of Health Research (CIHR)CompletedLatent Tuberculosis InfectionCanada, Australia, Benin, Brazil, Ghana, Guinea, Indonesia
-
McGill UniversityCanadian Institutes of Health Research (CIHR)CompletedLatent Tuberculosis InfectionCanada, Australia, Benin, Brazil, Ghana, Indonesia, Guinea, Korea, Republic of, Saudi Arabia
-
University of British ColumbiaBritish Columbia Cancer AgencyUnknownLatent Tuberculosis InfectionCanada
-
Samsung Medical CenterCompletedLatent Tuberculosis InfectionKorea, Republic of
-
Hospital Universitari de BellvitgeCellestisCompletedLatent Tuberculosis InfectionSpain
-
Ligue Pulmonaire GenevoiseCompletedLatent Tuberculosis InfectionSwitzerland
-
University Hospital, GenevaLigue Pulmonaire GenevoiseCompletedTuberculosis | Latent Tuberculosis InfectionSwitzerland
Clinical Trials on Rifapentine and Isoniazid for 3 months
-
Centers for Disease Control and PreventionUS Department of Veterans AffairsCompletedTuberculosisUnited States, Canada, Brazil, Spain
-
Centers for Disease Control and PreventionVA Office of Research and DevelopmentCompletedTuberculosisUnited States, Canada, Spain, Brazil
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Human Sciences...RecruitingTuberculosisSouth Africa
-
Huashan HospitalCompletedTuberculosis | SilicosisChina
-
The Aurum Institute NPCJohns Hopkins UniversityRecruitingTuberculosis | HIV Seropositivity | Household ContactSouth Africa, India, Indonesia, Mozambique
-
Huashan HospitalShanghai First Maternity and Infant HospitalUnknownInfertility, Female | Recurrent Implantation Failure | Genital Tuberculoses, Female | Genital Tuberculosis, LatentChina
-
Institut National de la Santé Et de la Recherche...Vertex Pharmaceuticals Incorporated; Fondation pour la Recherche Médicale; Fondation...TerminatedCystic FibrosisFrance
-
Centers for Disease Control and PreventionBritish Medical Research CouncilRecruitingLatent TuberculosisAustralia, United States, Canada, South Africa
-
Dr. Nyanda Elias NtinginyaKing's College London; Makerere University; Stichting Katholieke Universiteit-... and other collaboratorsRecruitingDiabetes Mellitus | TuberculosisUganda, Tanzania
-
The Miriam HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed